J&J drug unit to leverage Singapore's biotech hub
'Very lively biotech hub' spurs pharmaceutical arm's external collaborations
Annabeth Leow
Singapore
JOHNSON & Johnson's (J&J) regional pharmaceutical head believes that Singapore offers innovation, research and development tie-up opportunities, even as wider insurance coverage in the Asia-Pacific is expected to fuel growth for drugmakers.
Ong Ai Hua, the group chairman for Janssen Asia Pacific, the pharmaceutical arm of J&J, told The Business Times that "our focus in Singapore is on innovation - not so much on manufacturing".
TRENDING NOW
CSE Global independent director quits after clashes with chairman Eugene Lai over board refresh
‘I felt like dying’: Thai Singha beer scion speaks up after disclosure of alleged sexual abuse
Abandoned ‘Titanic’, failing ‘ancient towns’: Why China’s tourism boom leaves white elephants behind
Cat A COE rate exceeds Cat B for third time in 4 months; premiums largely down